High Expression of Heterogeneous Nuclear Ribonucleoprotein A1 Facilitates Hepatocellular Carcinoma Growth
Ziyi Cao,Li Guan,Runzhi Yu,Fan Yang,Jie Chen
DOI: https://doi.org/10.2147/JHC.S402247
2023-04-01
Journal of Hepatocellular Carcinoma
Abstract:Ziyi Cao, 1, &ast Li Guan, 1, &ast Runzhi Yu, 1 Fan Yang, 2 Jie Chen 1 1 Department of Gastroenterology, Huadong Hospital Affiliated to Fudan University, Shanghai, 200040, People's Republic of China; 2 Shanghai Key Laboratory of Clinical Geriatric Medicine, Shanghai, 200040, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jie Chen; Fan Yang, Email ; Purpose: Hepatocellular carcinoma (HCC) represents one of the most common tumors in the world. Our study aims to explore new markers and therapeutic targets for HCC. Heterogeneous Nuclear ribonucleoprotein A1 (hnRNPA1) has recently been found to be involved in the progression of several types of cancer, but its role in HCC remains uncovered. Methods: We performed bioinformatic analysis to preliminarily show the relationship between hnRNPA1 and liver cancer. Then the correlation of the hnRNPA1 gene expression with clinicopathological characteristics of HCC patients was verified by human liver cancer tissue microarrays. The functional role of this gene was evaluated by in vivo and vitro experiments. Results: Results showed that the expression of hnRNPA1 was upregulated in HCC tissues and was associated with pathological stage of HCC patients. Knockdown of hnRNPA1 gene markedly inhibited tumor growth in vivo, and reversed the effects on proliferation, migration and invasion and promoted apoptosis in vitro. Furthermore, down-regulation of hnRNPA1 gene expression can inhibit the activity of the MEK/ERK pathway. Conclusion: In our work, we combined bioinformatic analysis with in vivo and in vitro experiments to initially elucidate the function of hnRNPA1 in liver cancer, which may help to explore biomarkers and therapeutic targets for HCC patients. Keywords: hepatocellular carcinoma, WGCNA, hnRNPA1, proliferation, MEK/ERK Liver cancer remains a major global health challenge, even though considerable progress has been made in understanding its epidemiology, risk factors and molecular mechanisms during the past decades. It is estimated that the incidence of liver cancer will exceed 1 million by 2025. 1 Hepatocellular carcinoma (HCC) represents approximately 90% of all cases of primary liver cancer. 1–3 With a 5-year survival rate of 18%, liver cancer is the second most lethal tumor worldwide. 3,4 The outlook is even grimmer for patients from Asian countries such as China, where the 5-year survival rate is reported to be as low as 12%. 4 Under this circumstance, it is necessary to continue to explore the underlying mechanisms leading to HCC tumorigenesis in order to achieve new breakthroughs in HCC treatment. In recent years, microarray transcriptomics has been widely used in tumor research, and is more comprehensive and precise. Applying bioinformatics analysis to microarray expression patterns helps identify potential therapeutic targets. In this regard, weighted gene coexpression network analysis (WGCNA), is a powerful tool for constructing correlation networks and finding hub genes and is widely used in identifying biomarkers for cancers. 5–8 In our research, we obtained the clinical data and RNA-seq data (HT-seq FPKM) of patients with HCC from The Cancer Genome Atlas (TCGA) database, which contains 374 liver hepatocellular carcinoma (LIHC) tumor tissues and 50 normal tissues. WGCNA was subsequently used to process the data to discern hub genes. HnRNPA1, which was highly expressed in tumor tissues and correlated with tumor stage according to the analysis results, was ultimately selected as crucial gene of interest. HnRNPA1 belongs to the hnRNP family. HnRNPs are a large class of RNA-binding proteins, that mainly play a role in the transformation of hnRNA/pre-mRNAs into mature mRNAs, mRNA stabilization, transcription and posttranscriptional translation. 9,10 As the most critical alternative splicing (AS) regulator, hnRNPs are associated with a variety of tumor diseases, since cancer cells can hijack and alter the AS process to facilitate their proliferation and metastasis, according to recent studies, 11–13 and hnRNP expression levels are detected to be altered in various tumors. 14–16 HnRNPA1, as the most ubiquitously expressed member of the hnRNP family, has a well-established role in regulating RNA splicing, but other functions in mediating cellular signaling are only now being appreciated. 17 Emerging evidence suggests that hnRNPA1 is closely related to tumor progression. 17–19 For example, hnRNPA1 promotes cancer cell proliferation in endometrial cancer. 20 HnRNPA1 interacts with G-quadruplex in the TRA2B promoter -Abstract Truncated-
oncology